Product Images Venlafaxine Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Venlafaxine Hydrochloride NDC 68071-4164 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

68071 4164 3

68071 4164 3

Venlafaxine hydrochloride extended-release capsules, USP - venlafaxineercaps figure 01

Venlafaxine hydrochloride extended-release capsules, USP - venlafaxineercaps figure 01

This is a drug interaction table that provides information about the effects of certain drugs (Ethanol, Diazepam, Cimetidine, Ketoconazole, Indinavir, Metoprolol, Imipramine, and Lithium) on the activity of the liver enzyme CYP2D6. The table also shows the effects of these drugs on the blood levels of venlafaxine, and provides PK Fold Change and 90% C recommendations for these drugs. Clinical significance is unknown for some of these drugs, and caution is recommended when using them in patients with hypertension, elderly, or hepatic dysfunction. No dose adjustment is necessary for some drugs.*

Venlafaxine hydrochloride extended-release capsules, USP - venlafaxineercaps figure 02

Venlafaxine hydrochloride extended-release capsules, USP - venlafaxineercaps figure 02

This text appears to be a list of drugs and their interactions with other drugs. The drugs listed include ethanol, diazepam, alprazolam, indinavir, metoprolol, risperidone, imipramine, haloperidol, caffeine, and lithium. The text provides information on the PKFold change and the 90% C recommendation for these drugs. The text also includes information on whether concomitant use is recommended, whether there is a need for dose adjustment or cautionary use, and clinical significance for each drug, with some details on active moieties.*

Venlafaxine hydrochloride extended-release capsules, USP - venlafaxineercaps figure 03

Venlafaxine hydrochloride extended-release capsules, USP - venlafaxineercaps figure 03

This is a clinical pharmacology report discussing the effects of various conditions on the metabolization and recommended dosing of the drug venlafaxine. Factors discussed include liver and kidney impairment, age, gender, and genetic variations in metabolism. The report provides fold change and 90% confidence intervals for recommended dose adjustment in different scenarios.*

Venlafaxine hydrochloride extended-release capsules, USP - venlafaxineercaps figure 04

Venlafaxine hydrochloride extended-release capsules, USP - venlafaxineercaps figure 04

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.